Top

Published in:

01-11-2016 | Review Article

The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis

Authors: B. M. Musa, N. A. Galadanci, M. Coker, S. Bussell, M. H. Aliyu

Published in: Annals of Hematology | Issue 11/2016

Abstract

Elevated tricuspid regurgitant jet velocity (TRJV) is a surrogate measure of pulmonary hypertension (PH) in persons with sickle cell disease (SCD). We sought to estimate the burden of PH in people living with sickle cell disease based on TRJV. From 2000 to 2015, we searched electronic databases for eligible publications and included 29 studies (n = 5358 persons). We used random effects modeling to determine the pooled estimate of elevated TRJV. The overall pooled prevalence of elevated TRJV was 23.5 %(95 % CI 19.5–27.4) in persons with SCD. The pooled prevalence of elevated TRJV in children and adults with SCD was 20.7 % (95 % CI 15.7–-25.6) and 24.4 % (95 % CI 18.4–30.4), respectively. TRJV is prevalent among adults and children with SCD. Our finding support international recommendations that call for screening for PH in SCD patients.

Aessopos A, Farmakis D, Karagiorga M et al (2001) Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 97:3411–3416CrossRefPubMed

WHO | Sickle-cell disease and other haemoglobin disorders. In: WHO. http://www.who.int/mediacentre/factsheets/fs308/en/. Accessed 6 Jan 2016

Yater W, Hansmann G (1936) Sickle cell anemia: a new cause of cor pulmonale: report of two cases with numerous disseminated occlusions of the small pulmonary arteries. Am J Med Sci 191:474–484CrossRef

Gladwin MT (2008) Current and future therapies of sickle cell anemia: an historical perspective. Hematology Am Soc Hematol Educ Program 176. doi: 10.1182/asheducation-2008.1.176

Haque AK, Gokhale S, Rampy BA et al (2002) Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33:1037–1043CrossRefPubMed

Rother RP, Bell L, Hillmen P, Gladwin MT (2005) The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293:1653–1662. doi:10.1001/jama.293.13.1653 CrossRefPubMed

Reiter CD, Wang X, Tanus-Santos JE et al (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8:1383–1389. doi:10.1038/nm799 CrossRefPubMed

Powars D, Weidman JA, Odom-Maryon T et al (1988) Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 67:66–76CrossRef

Mehari A, Gladwin MT, Tian X et al (2012) Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 307:1254–1256. doi:10.1001/jama.2012.358 CrossRefPubMedPubMedCentral

10.

Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117. doi:10.1056/NEJM199701093360207 CrossRefPubMed

11.

Simmons BE, Santhanam V, Castaner A et al (1988) Sickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch Intern Med 148:1526–1528CrossRefPubMed

12.

Gladwin MT, Sachdev V, Jison ML et al (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350:886–895. doi:10.1056/NEJMoa035477 CrossRefPubMed

13.

Ataga KI, Moore CG, Jones S et al (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 134:109–115. doi:10.1111/j.1365-2141.2006.06110.x CrossRefPubMed

14.

Castro O, Gladwin MT (2005) Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 19:881–896. doi:10.1016/j.hoc.2005.07.007, ViiCrossRefPubMed

15.

Fonseca GHH, Souza R, Salemi VMC et al (2012) Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 39:112–118. doi:10.1183/09031936.00134410 CrossRefPubMed

16.

Suell MN, Bezold LI, Okcu MF et al (2005) Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol 27:654–658CrossRefPubMed

17.

Ambrusko SJ, Gunawardena S, Sakara A et al (2006) Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer 47:907–913. doi:10.1002/pbc.20791 CrossRefPubMed

18.

Sedrak A, Rao SP, Miller ST et al (2009) A prospective appraisal of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol 31:97–100. doi:10.1097/MPH.0b013e31818e5343 CrossRefPubMed

19.

Desai AA, Zhou T, Ahmad H et al (2012) A novel molecular signature for elevated tricuspid regurgitation velocity in sickle cell disease. Am J Respir Crit Care Med 186:359–368. doi:10.1164/rccm.201201-0057OC CrossRefPubMedPubMedCentral

20.

Cabrita IZ, Mohammed A, Layton M et al (2013) The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. Br J Haematol 162:400–408. doi:10.1111/bjh.12391 CrossRefPubMed

21.

Enakpene EO, Adebiyi AA, Ogah OS et al (2014) Non-invasive estimation of pulmonary artery pressures in patients with sickle cell anaemia in Ibadan, Nigeria: an echocardiographic study. Acta Cardiol 69:505–511PubMed

22.

Soh MC, Sankaran S, Nelson-Piercy C, Oteng-Ntim E (2014) The prevalence of raised tricuspid regurgitation velocity in pregnant women with sickle cell disease and its association with obstetric outcomes-an observational study. Societies of Obstetric Medicine combined 2014 meeting in New Orleans, Louisiana, USA: Obstetric Medicine: The Medicine of Pregnancy 8:28–50. doi:10.1177/1753495X14566755

23.

Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A (2008) Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics 121:777–782. doi:10.1542/peds.2007-0730 CrossRefPubMed

24.

Aliyu ZY, Gordeuk V, Sachdev V et al (2008) Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol 83:485–490. doi:10.1002/ajh.21162 CrossRefPubMedPubMedCentral

25.

Onyekwere OC, Campbell A, Teshome M et al (2008) Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 29:309–312. doi:10.1007/s00246-007-9018-x CrossRefPubMed

26.

Liem RI, Nevin MA, Prestridge A et al (2009) Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. Pediatr Pulmonol 44:281–289. doi:10.1002/ppul.20996 CrossRefPubMed

27.

Minniti CP, Sable C, Campbell A et al (2009) Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 94:340–347. doi:10.3324/haematol.13812 CrossRefPubMedPubMedCentral

28.

Naoman SG, Nouraie M, Castro OL et al (2010) Echocardiographic findings in patients with sickle cell disease. Ann Hematol 89:61–66. doi:10.1007/s00277-009-0764-0 CrossRefPubMed

29.

Parent F, Bachir D, Inamo J et al (2011) A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 365:44–53. doi:10.1056/NEJMoa1005565 CrossRefPubMed

30.

Gordeuk VR, Minniti CP, Nouraie M et al (2011) Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica 96:33–40. doi:10.3324/haematol.2010.030767 CrossRefPubMed

31.

Sachdev V, Kato GJ, Gibbs JSR et al (2011) Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation 124:1452–1460. doi:10.1161/CIRCULATIONAHA.111.032920 CrossRefPubMedPubMedCentral

32.

Al-Khoufi EAS (2013) Prevalence of pulmonary arterial hypertension among sickle cell disease patients in Al Hassa. Glob J Health Sci 5:174–180. doi:10.5539/gjhs.v5n5p174 PubMedPubMedCentral

33.

Sharma S, Efird J, Kadali R et al (2013) Pulmonary artery occlusion pressure may overdiagnose pulmonary artery hypertension in sickle cell disease. Clin Cardiol 36:524–530. doi:10.1002/clc.22153 CrossRefPubMed

34.

Cox SE, Soka D, Kirkham FJ et al (2014) Tricuspid regurgitant jet velocity and hospitalization in Tanzanian children with sickle cell anemia. Haematologica 99:e1–4. doi:10.3324/haematol.2013.089235 CrossRefPubMedPubMedCentral

35.

Gladwin MT, Barst RJ, Gibbs JSR et al (2014) Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS ONE 9:e99489. doi:10.1371/journal.pone.0099489 CrossRefPubMedPubMedCentral

36.

Marouf R, Behbehani N, Zubaid M et al (2014) Transthoracic echocardiography and 6-minute walk test in Kuwaiti sickle cell disease patients. Med Princ Pract 23:212–217. doi:10.1159/000362126 CrossRefPubMed

37.

Upadhya B, Stacey RB, Ntim W et al (2014) Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease. Acta Haematol 132:152–158. doi:10.1159/000357393 CrossRefPubMed

38.

Agha H, El Tagui M, El Ghamrawy M, Abdel Hady M (2014) The 6-min walk test: an independent correlate of elevated tricuspid regurgitant jet velocity in children and young adult sickle cell patients. Ann Hematol 93:1131–1138. doi:10.1007/s00277-014-2030-3 PubMed

39.

Molavi MA, Rajaei S, Elahi Z, et al (2015) Evaluation of tricuspid regurgitation jet velocity in children with sickle cell disease in Iran 2012-2013. Advances in Bioresearch 6(5);211

40.

Mushemi-Blake S, Melikian N, Drasar E, et al (2015) Pulmonary haemodynamics in sickle cell disease are driven predominantly by a high-output state rather than elevated pulmonary vascular resistance: a prospective 3-dimensional echocardiography/doppler study. PLoS One. doi: 10.1371/journal.pone.0135472

41.

Hebson C, New T, Record E et al (2015) Elevated tricuspid regurgitant velocity as a marker for pulmonary hypertension in children with sickle cell disease: less prevalent and predictive than previously thought? J Pediatr Hematol Oncol 37:134–139. doi:10.1097/MPH.0000000000000184 CrossRefPubMed

42.

Barth RE, Huijgen Q, Taljaard J, Hoepelman AIM (2010) Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14:e1024–1031. doi:10.1016/j.ijid.2010.06.013 CrossRefPubMed

43.

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114. doi:10.1016/j.cct.2006.04.004 CrossRefPubMed

44.

Cohn LD, Becker BJ (2003) How meta-analysis increases statistical power. Psychol Methods 8:243–253. doi:10.1037/1082-989X.8.3.243 CrossRefPubMed

45.

Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed

46.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

47.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentral

48.

Sutton LL, Castro O, Cross DJ et al (1994) Pulmonary hypertension in sickle cell disease. Am J Cardiol 74:626–628CrossRefPubMed

49.

Castro O (1996) Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am 10:1289–1303CrossRefPubMed

50.

Hagar RW, Michlitsch JG, Gardner J et al (2008) Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. Br J Haematol 140:104–112. doi:10.1111/j.1365-2141.2007.06822.x PubMed

51.

Rhodes CJ, Wharton J, Wilkins MR (2013) Pulmonary hypertension: biomarkers. Handb Exp Pharmacol 218:77–103. doi:10.1007/978-3-642-38664-0_4 CrossRefPubMed

52.

Janda S, Shahidi N, Gin K, Swiston J (2011) Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Heart 97:612–622. doi:10.1136/hrt.2010.212084 CrossRefPubMed

53.

Klings ES, Machado RF, Barst RJ et al (2014) An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 189:727–740. doi:10.1164/rccm.201401-0065ST CrossRefPubMedPubMedCentral

54.

Machado RF, Barst RJ, Yovetich NA et al (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118:855–864. doi:10.1182/blood-2010-09-306167 CrossRefPubMedPubMedCentral

55.

Bunn HF, Nathan DG, Dover GJ et al (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 116:687–692. doi:10.1182/blood-2010-02-268193 CrossRefPubMed

56.

Machado R, Barst R, Yovetich N, et al (2009) Safety and efficacy of sildenafil therapy for Doppler-defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk- PHaSST clinical trial. American Society of Hematology. In: Top 10 clinically oriented abstracts in sickle cell disease. American Journal of Hematology, n New Orleans, Louisiana, USA, pp 204–205

Title: The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis
Authors: B. M. Musa
N. A. Galadanci
M. Coker
S. Bussell
M. H. Aliyu
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 11/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-016-2693-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2016

Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia

Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study

Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report

Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia

Erratum to: Which pamidronate protocol is the best for treating osteoporosis in beta-thalassemia major?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage